Ann: Appendix 4D and Half Year Report, page-4

MedAdvisor has never really had ‘cash’, at least not at the levels seen now.

What are they going to do with $33M?

• Pay out/down debt ($13M)
• New product development
• Grow sales teams to target more revenue
• Break through in new markets (UK)
• New acquisition
• Rainy day war chest

They still need to demonstrate $40M+ revenue in H2 to show what’s earned in December isn’t eroded. Costs of doing business and inflation is on the rise. I suspect they might plan a price rise for AU/NZ pharmacies using PlusOne.